Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
Authors:
Top Cited Papers
- 30 January 2024
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 11 (3) , e146-e155
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
This publication has 25 references indexed in Scilit:
- Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsNature Medicine, 2018
- Combination therapy with anti-HIV-1 antibodies maintains viral suppressionNature, 2018
- A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging PopulationInfectious Diseases and Therapy, 2018
- Antibody 10-1074 suppresses viremia in HIV-1-infected individualsNature Medicine, 2017
- HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionNature, 2016
- Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Nature, 2015
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infectionAIDS, 2014
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusNature, 2013
- Rapid evolution of the neutralizing antibody response to HIV type 1 infectionProceedings of the National Academy of Sciences, 2003
- A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2000